Carregant...
Disclosure of Industry Payments to Prescribers: Industry Payments Might be a Factor Impacting Generic Drug Prescribing
PURPOSE: Pharmaceutical companies paid at least $3.91 billion to prescribers in 2013, yet evidence indicating whether industry payments shift prescribing away from generics is limited. This study examined the association between amount of industry payments to prescribers and generic drug prescribing...
Guardat en:
| Publicat a: | Pharmacoepidemiol Drug Saf |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5856251/ https://ncbi.nlm.nih.gov/pubmed/28485111 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4224 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|